Starpharma Holdings Price to Free Cash Flow Ratio 2011-2022 | SPHRY
Historical price to free cash flow ratio values for Starpharma Holdings (SPHRY) since 2011.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Starpharma Holdings Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
|
0.00 |
|
nan |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.189B |
$0.004B |
|
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
|
